Lyell Immunopharma, Inc. $LYEL Shares Sold by TD Asset Management Inc

Key Points

• TD Asset Management Inc significantly reduced its stake in Lyell Immunopharma by 95% during the second quarter, now owning only 50,232 shares worth approximately $444,000.
• Lyell Immunopharma's shares rose 7.6%, and the company reported earnings of ($2.89) per share, exceeding analyst estimates.
• Analysts have given Lyell a consensus rating of “Sell” with an average price target of $15.00.

TD Asset Management Inc cut its position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 95.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,232 shares of the company's stock after selling 954,410 shares during the quarter. TD Asset Management Inc owned about 0.34% of Lyell Immunopharma worth $444,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its stake in Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company's stock worth $94,000 after acquiring an additional 154,327 shares during the last quarter. Nuveen LLC acquired a new stake in Lyell Immunopharma during the first quarter worth about $345,000. Acadian Asset Management LLC increased its stake in Lyell Immunopharma by 204.2% during the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company's stock worth $354,000 after acquiring an additional 443,614 shares during the last quarter. Finally, Almitas Capital LLC increased its stake in Lyell Immunopharma by 136.3% during the first quarter. Almitas Capital LLC now owns 2,482,606 shares of the company's stock worth $1,336,000 after acquiring an additional 1,432,086 shares during the last quarter. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Lyell Immunopharma Stock Up 7.6%

Shares of NASDAQ LYEL opened at $18.32 on Friday. Lyell Immunopharma, Inc. has a fifty-two week low of $7.65 and a fifty-two week high of $30.00. The business has a 50 day moving average price of $13.97 and a two-hundred day moving average price of $11.07. The firm has a market cap of $351.95 million, a PE ratio of -0.75 and a beta of -0.07.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($2.89) earnings per share for the quarter, beating analysts' consensus estimates of ($3.80) by $0.91. Lyell Immunopharma had a negative return on equity of 85.58% and a negative net margin of 552,328.31%.The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. On average, analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on LYEL shares. Weiss Ratings restated a "sell (d-)" rating on shares of Lyell Immunopharma in a research note on Wednesday, October 8th. Wall Street Zen raised Lyell Immunopharma from a "sell" rating to a "hold" rating in a research report on Monday, September 1st. One analyst has rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Sell" and an average price target of $15.00.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

Want to see what other hedge funds are holding LYEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.